Recently, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (Sanyou) and
Shanghai KangaBio Co., Ltd. (KangaBio) have reached an antibody drug
licensing agreement, regarding a proprietary monoclonal antibody drug
developed by Sanyou, which grants KangaBio an exclusive license to
exploit the antibody for research, development, manufacturing and
commercialization of immunotherapy products. KangaBio, as a rising star
biotechnology company, is committed to developing innovative prodrugs
and providing innovative medicine to address unmet clinical needs. While
Sanyou is a biological high-tech company focusing on innovative
antibody drugs R&D services. Based on the two companies’ respective
strengths and industry resources, Sanyou and KangaBio will work together
to contribute to the development of innovative prodrugs for
immunotherapy.
Previously, KangaBio and Sanyou reached a collaboration agreement on
two monoclonal antibody drugs developed by Sanyou and signed high-level
term sheet. In addition to the license transfer of drug candidates, the
two companies have also successively reached to collaborative
development, commissioned R&D, technical services and other forms of
staged R&D collaboration. Sanyou fully exploits its 6 types of
one-stop innovative antibody drug integrated services, 11 types of
flexible and adaptable antibody drug R&D staged technical services
and 11 types of diverse antibody generation featured services to fully
support the drug development of KangaBio.
Dr. Weidong Jiang, founder and CEO of KangaBio, said,"We
are looking forward to this collaboration. KangaBio is committed to
developing low toxicity and high efficacy immuno-agonists and innovative
prodrugs of multi-specific antibodies. This strategic partnership with
Sanyou is expected to utilize the advantages of Sanyou’s internationally
leading innovative antibody drug development and value transformation
platform, to further enrich KangaBio’s innovative product pipeline, to
accelerate the R&D of our innovative antibody drugs and to address
unmet clinical needs."
Dr. Guojun Lang, founder and CEO of Sanyou, said,"
We are extremely honored to collaborate with KangaBio again. During the
past numerous collaborations, Sanyou has saved valuable time with the
pre-clinical drug R&D for KangaBio, owing to the comprehensive
innovative drug development system and rich industrialization
experiences. The close collaboration also demonstrates the strong
complementary character of our business layout. We look forward to more
in-depth communication and collaboration with KangaBio in the future and
wish that this collaboration will bring benefits to the development of
KangaBio. Sanyou and Kanga will team up to accomplish remarkable
achievements."
About KangaBio
KangaBio was founded in 2021 by Dr. Weidong Jiang. KangaBio is a
biotech company focused on providing innovative medicine to address
unmet medical needs. KangaBio is committed to developing prodrugs of
immune-stimulating agents and other multi-specific biologics to avoid
toxicities for previously validated targets and to increase drug
efficacy. Dr. Weidong Jiang,B.S. from Hangzhou University (Zhejiang
University),M.S. from Shanghai Institute of Cell Biology, Chinese
Academy of Sciences,Ph.D. from Giessen University, Germany,Post-doc from
University of California,Worked at ChemGenics (Millennium/Takeda),
Microcide, Applied Molecular Evolution (Eli Lilly) and Catalyst
Biosciences as Sr. Scientist and Director, with extensive record of
successful drug research and development. Dr. Jiang previously
co-founded Shanghai Henlius Biotech in 2009, a public company exchange
with five successfully launched biologics in the Chinese market as well
as one in the European market. Today, KangaBio is in a vigorous and
rapid development stage under the leadership of Dr. Jiang.
About Sanyou Biopharmaceuticals
Sanyou Biopharmaceuticals Co., Ltd. is a biological high-tech
enterprise focusing on R&D and services of innovative antibody
drugs. Sanyou is committed to establishing an internationally leading
high-quality, high-throughput, integrated R&D and value
transformation platform for innovative antibody drugs, constructing a
business ecosystem involving therapy, R&D, and diagnostic products
and services, and cooperating with global biopharmaceutical, diagnostic,
and drug R&D companies to make a new progress in the diagnosis and
treatment of human diseases. Sanyou has established an integrated
innovative antibody drug R&D laboratory of over 20,000 square meters
with advanced facilities and equipment, and more than 40 core
innovation technology platforms, including platforms for innovative
antibody drug discovery featured with a series of trillion-level phage
display antibody libraries, innovative antibody drug optimization, cell
line construction, upstream and downstream process development,
preclinical R&D and industrial development.